Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Hanna

Interventional Pain Medicine Clifton, NJ Medical Doctor

NPI 1902033723 CMS profile 474565

1117 Route 46 Ste 205, Clifton, NJ 07013

Open in the dashboard

General payments

$4,906

65 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Hanna of Clifton, NJ is reported in the CMS Open Payments database as having received $4,906 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $204 3
2024 General $71 3
2023 General $2,190 18
2022 General $898 13
2021 General $518 12
2020 General $762 11
2019 General $262 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Hanna
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to George Hanna were reported at $204. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year George Hanna Interventional Pain Medicine median Middle half National median
2019 $262 $684 $216–$2,079 $163
2020 $762 $382 $122–$1,109 $114
2021 $518 $552 $167–$1,554 $132
2022 $898 $605 $187–$1,924 $149
2023 $2,190 $671 $195–$1,915 $160
2024 $71 $684 $206–$1,837 $164
2025 $204 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $1,717 12 payments
  2. Vertos Medical, Inc. $834 10 payments
  3. Abbott Laboratories $749 8 payments
  4. Nevro Corp. $222 3 payments
  5. Tactile Systems Technology Inc $216 4 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $185 10 payments
  7. Medtronic USA, Inc. $181 4 payments
  8. NuVasive, Inc. $135 1 payment
  9. Boston Scientific Corporation $131 1 payment
  10. Painteq LLC $114 1 payment
  11. Other $421 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,715 60 payments
  2. Travel and Lodging $1,191 5 payments
Products named General payments · program years 2019–2025
  1. VENASEAL $1,689 11 payments
  2. mild Device Kit $834 10 payments
  3. Proclaim IPG $350 4 payments
  4. Senza Spinal Cord Stimulation System $222 3 payments
  5. Flexitouch Plus $216 4 payments
  6. Entre Plus $189 2 payments
  7. JARDIANCE $185 10 payments
  8. Proclaim Family of SCS IPGs $172 1 payment
  9. ACP $135 1 payment
  10. GENERAL - PAIN MANAGEMENT $131 1 payment
  11. Other $959 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$88,796

Of which drugs: $17,797

Medicare patients

110

Average age 75

Services billed

5,582

73 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Diabetes 35%
Ischemic heart disease 35%
Osteoporosis 26%
Cancer 18%
Depression 18%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 13 2,575 $11,006
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 12 82 $4,747
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 1,920 $197
Injection, methylprednisolone acetate, 40 mg J1030 Office 13 14 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record